Enterprise Europe Network

Carbosilane dendrons functionalized with fatty acids: Formation of micelles and uses in biomedicine as antiviral, antibacterial, antiprionic, antimicrobial and drug transporters.

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20181015002
Published
15/10/2018
Last update
24/10/2019
Expiration date
01/05/2020

Keywords

Partner keyword: 
Pharmaceutical Products / Drugs
Virus, Virology/Antibiotics/Bacteriology
Drug delivery and other equipment
EXPRESS YOUR INTEREST

Summary

Summary: 
A research group of a Spanish university has developed an invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives. The group seeks to reach license agreements, research cooperation agreements or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.

Description

Description: 

The Spanish research group provides compounds formed by dendrons of carbosilane structure that are functionalized in their periphery with anionic groups (such as carboxylate, sulfonate or sulfate), which endow the system with a net negative charge, or cationic (such as ammonium), which endow the system with a positive net charge.
These dendrons present a focal point that contains a hydrophobic function, mainly derived from a fatty acid. The fatty acid is linked to the dendron preferably through an ester bond, without dismissing other types of bonds, or even through electrostatic interactions.
Another aspect of the present invention relates to the process for obtaining the compounds.
The patent also includes the preparation of Janus type dendrimers, which are characterized by being formed by two dendritic units that have some distinct structural features.
And finally, the invention includes the ability of the described compounds to form micelles. The principal medium for its formation would be aqueous but micelles can also be formed in solutions containing soluble salts in these media or surfactants.
Regarding the uses in biomedicine of these compounds and the micelles formed by them, it is worth highlighting: their use as non-viral transport agents for the transfection or internalization of nucleic material within different cell lines in gene therapy processes; use of these compounds as "per se" therapeutic agents, for example as antiviral, antimicrobial or antipyretic agents, or as drug transporters, even for the preparation of a drug of solid or liquid composition. And oral, nasal, topical or parenteral administration.
In their environmental application, they can be used as biocides to prevent the appearance of microorganisms on surfaces or water treatment.

The research group seeks to reach licensing, research cooperation agreements or commercial agreements with technical assistance, with companies and institutions in the biomedical, pharmaceutical, biotechnological and environmental sectors to foster the exploitation of this invention.

Advantages & innovations

Cooperation plus value: 
These systems are able to overcome some of the difficulties that certain drugs found, allowing to facilitate their transport, favoring their solubility, increasing their solubility and even acting as transporters to the areas of interest. these competitive advantages are listed below: - Ease of diffusion of dendrimers through biological barriers, and therefore access to target cells. - Possibility of encapsulation and transport of drugs or other molecules with biological activity. - The preparation of these dendrimers as pharmaceutical formula can be very varied, being possible any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels, solutions, suspensions or emulsions). For oral, nasal, topical or parenteral administration.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The research group seeks to reach licensing, research cooperation agreements or commercial agreements with technical assistance, with companies and institutions in the biomedical, pharmaceutical, biotechnological and environmental sectors. Companies of the target sectors previously mentioned are seeking to exploit the results of the invention via licensing and/or commercial agreements with technical cooperation. Research institutions or companies with a solid R&D background are sought for cooperation agreements in order to foster the technology already developed to a next stage.

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500